Reproductive health experts collaborate in multi-centre study with Gene Solutions to develop next-generation prenatal genetic screening test that predicts for adverse pregnancy complications

March 18, 2024 04:01 PM PDT | By Cision
 Reproductive health experts collaborate in multi-centre study with Gene Solutions to develop next-generation prenatal genetic screening test that predicts for adverse pregnancy complications
Image source: Kalkine Media

SINGAPORE, March 19, 2024 /PRNewswire/ -- Gene Solutions announced a multi-centre research collaboration with leading OBGYN centres in Vietnam, Singapore, Indonesia, and Philippines on the early prediction of pregnancy complications.  This clinical study involving >10,000 women would be the first of its kind, focusing on maternal health, enabling earlier prediction of potential pregnancy complications.

Dr. Hoa Giang, HCMC Medical Genetics Institute, co-founder of Gene Solutions.
Dr. Hoa Giang, HCMC Medical Genetics Institute, co-founder of Gene Solutions.

At the workshop "Beyond the First-line Prenatal Screening" held in Singapore on March 15, 2024, 70 obstetricians and leading geneticists from Vietnam, Indonesia, the Philippines shared about the pathogenesis, clinical burden, and new evidence in prediction of Severe Pregnancy Syndromes. Dr. Anna Belen I. Alensuela, Board Member of Philippine Obstetrical and Gynecology Society, cited studies where more than 15% of pregnancies suffer from great obstetrical syndromes causing severe adverse short and long-term outcomes for both the mother and fetus1. These syndromes are the clinical endpoints of several underlying mechanisms including deep placentation dysfunctions.

“Beyond the First-Line Prenatal Screening” scientific workshop held in Singapore on Mar 15, 2024.
“Beyond the First-Line Prenatal Screening” scientific workshop held in Singapore on Mar 15, 2024.

"According to current guidelines, screening for the risk of premature birth, pre-eclampsia and gestational diabetes usually takes place in the later stages of pregnancy, while identifying high-risk patients early in the first trimester help in better identification and management of pregnancies under modern care model." - shared Prof. Dr. Noroyono Wibowo, Head of Maternal Fetal Medicine of University of Indonesia. 

Associate Professor Dr. Matthew Warren Kemp from the National University of Singapore presented research data demonstrating that biomarkers in maternal blood may be used as effective prediction models for pathological risks in severe pregnancy syndromes including preeclampsia and chorioamnionitis. This could potentially lead to advancements in early detection of pregnancy complications before clinical presentation. 

To address these considerations, Dr. Hoa from HCMC Medical Genetics Institute, co-founder of Gene Solutions shared preliminary data of multi-omic biomakers for early prediction of pregnancy complications and announced the multi-center research program "Building and Evaluating an Early Prediction Model for Pregnancy Complications: Pre-eclampsia, Preterm Birth, and Gestational Diabetes in Non-Invasive Prenatal Testing (NIPT)". This two-phase study will run from 2024 to 2026, across South-East Asia, laying the groundwork for next-generation NIPT as a triage screen in early prediction of pregnancy complications.

About Gene Solutions

Gene Solutions is a leading company in the field of genetics in Southeast Asia, offering comprehensive genetic solutions in reproductive health care, assisted reproduction (IVF), cancer-risk screening and diagnosis, genetic disease research and diagnosis. More than a million triSure NIPT tests for first trimester prenatal screening have been performed for pregnant women since 2018. Gene Solutions remains committed to bringing clinically relevant genomics solutions and supporting access to precision medicine.

Media Contact:
Ms. Jean Huang
[email protected]

1Mastrolia SA, Cetin I. The "Great Obstetrical Syndromes". In: Petraglia F, Fauser BC, editors. Female Reproductive Dysfunction. Cham: Springer International Publishing; 2020. p. 411-30.  


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Sponsored Articles


Investing Ideas

Previous Next